Coronavirus Disease 2019 (COVID-19) Clinical Trial Oversight at a Major Academic Medical Center: Approach of Michigan Medicine
Kayte Spector‐Bagdady, Peter Higgins, Keith D. Aaronson, Judy Birk, Kevin R. Flaherty, Kevin Gregg, Robert C. Hyzy, Daniel Kaul, Adam S. Lauring, John C. Magee, William J Meurer, Pauline K. Park, Phillip Scott, Anna S. Lok
Abstract
Clinicians, eager to offer the best care in the absence of guiding data, have provided patients with coronavirus disease 2019 (COVID-19) diverse clinical interventions. This usage has led to perceptions of efficacy of some interventions that, while receiving media coverage, lack robust evidence. Moving forward, randomized controlled clinical trials are necessary to ensure that clinicians can treat patients effectively during this outbreak and the next. To do so, academic medical centers must address 2 key research issues: (1) how to effectively and efficiently determine which trials have the best chance of benefiting current and future patients and (2) how to establish a transparent and ethical process for subject recruitment while maintaining research integrity and without overburdening patients or staff. We share here the current methods used by Michigan Medicine to address these issues.